The following was in IBD News Weekly Digest in Sep
Post# of 72440
(Total Views: 492)
Posted On: 12/11/2019 3:43:53 PM
The following was in IBD News Weekly Digest in September. This is a paid site but I included the headline for those that want to follow up on it.
———————————-
IBD Updates
Contents:
Innovation Pharma Planning 1st Clinical Trial of Oral Brilacidin as Potential Ulcerative Colitis Treatment
Sep 20, 2019 07:00 am | Joana Carvalho, MSc
Innovation Pharmaceuticals is planning a first clinical trial of an oral formulation of Brilacidin as a treatment for ulcerative colitis (UC), one of the most common types of inflammatory bowel disease (IBD). Brilacidin is a synthetic small molecule that belongs to a new class of compounds known as defensin-mimetics. It is structurally similarity to proteins naturally produced in […]
The post Innovation Pharma Planning 1st Clinical Trial of Oral Brilacidin as Potential Ulcerative Colitis Treatment appeared first on IBD News Today.
———————————-
IBD Updates
Contents:
Innovation Pharma Planning 1st Clinical Trial of Oral Brilacidin as Potential Ulcerative Colitis Treatment
Sep 20, 2019 07:00 am | Joana Carvalho, MSc
Innovation Pharmaceuticals is planning a first clinical trial of an oral formulation of Brilacidin as a treatment for ulcerative colitis (UC), one of the most common types of inflammatory bowel disease (IBD). Brilacidin is a synthetic small molecule that belongs to a new class of compounds known as defensin-mimetics. It is structurally similarity to proteins naturally produced in […]
The post Innovation Pharma Planning 1st Clinical Trial of Oral Brilacidin as Potential Ulcerative Colitis Treatment appeared first on IBD News Today.
(8)
(1)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼